Table 2.

Postoperative outcomes and pathological characteristics (n = 850)

Variables
Pathological diagnosis, n (%)
Benign	271 (31.9%)
NSCLC	183 (21.5%)
Metastasis	380 (44.7%)
Other lung cancers#	16 (1.9%)
Postoperative complications during index hospitalization, n (%)
Pulmonary complications	60 (7.1%)
Pneumothorax	17 (2.0%)
Pneumonia	25 (2.9%)
Pleural effusion	5 (0.6%)
Oxygen dependency	36 (4.2%)
Cardiac complications	11 (1.3%)
Atrial fibrillation	11 (1.3%)
Gastrointestinal complications	36 (4.2%)
Constipation/Diarrhoea	15 (1.8%)
PONV	21 (2.5%)
Cecum volvulus	1 (0.1%)
Urinary complications	25 (2.9%)
Urinary tract infection	7 (0.8%)
Urinary retention	17 (2.0%)
Acute kidney failure	2 (0.2%)
Neurological complications	15 (1.8%)
Cognitive confusion/Delirium	13 (1.5%)
Stroke	2 (0.2%)
Postoperative bleeding	24 (2.8%)
Treated by tranexamic acid	20 (2.3%)
Treated by operation	4 (0.5%)
Wound complications	8 (0.9%)
Pain treated by opioid on POD 1	128 (15.1%)
LOS, day, median (IQR)	1 (1–2)
Duration of chest drainage, day, median (IQR)	1 (1–1)
90-day readmission, n (%)	86 (10.1%)
0–30-day readmission	66 (7.8%)
31–90-day readmission	27 (3.2%)
Time to first 90-day readmission, day, median (IQR)	13 (5–29)
Time to first 0–30-day readmission	8 (4–16)
Time to first 31–90-day readmission	40 (28–67)
LOS of 90-day readmission, day, median (IQR)	4 (2–6)
0–30-day readmission	3 (2–7)
31–90-day readmission	4 (2–6)
Mortality up to POD 90, n (%)	7 (0.8%)

#Other lung cancers included eight non-small cell lung cancer with uncertain original, two small cell lung cancer, one sarcoma, three mixed of primary non-small cell lung cancer and metastasis, one mixed of amyloid tumour and lymphoma, and one B-cell lymphoma

IQR interquartile range; LOS length of stay; NSCLC non-small cell lung cancer; POD postoperative day; PONV postoperative nausea and vomiting